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Abstract
Kisspeptin, originally identified as metastatin, important in
preventing cancer metastasis, has more recently been shown
to be important in pregnancy. Roles indicated for kisspeptin
in pregnancy include regulating trophoblast invasion and
migration during placentation. The pregnancy-specific
disorder pre-eclampsia (PE) is now accepted to begin with
inadequate trophoblast invasion and the current study
therefore sets out to characterise placental expression of
both kisspeptin (KISS1) and its receptor (KISS1R) through-
out pregnancy and in PE. Placental tissue was obtained from
women undergoing elective surgical termination of early
pregnancy (nZ10) and from women following Caesarean
section at term in normal pregnancy (nZ10) and with
PE (nZ10). Immunohistochemistry of paraffin embedded
sections and western immunoblotting were performed to
assess protein localisation and expression. Quantitative real-
time PCR was carried out to evaluate mRNA expression of
both KISS1 and KISS1R. Protein and mRNA expression
was found to mirror each other with KISS1 expression found
to be reduced in PE compared with that in normal term
pregnancy. Interestingly, KISS1R expression at both the
mRNA and protein levels was found to be increased in
PE compared with that in normal term pregnancy. The
current findings of increased KISS1R expression may
represent a mechanism by which functional activity of
KISS1 is higher in PE than in normal pregnancy. Higher
levels of activity of KISS1R may be involved in inhibition of
trophoblast invasion and angiogenesis, which are associated
with PE.
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Introduction
The primary translation product of KISS1 is a 145 amino acid
polypeptide known as Kp-145. Kisspeptins (KISS1), which
are biologically active, containing 54 (Kp-54), 14 (Kp-14),
13 (Kp-13) and ten (Kp-10) amino acids, are then produced
by post-translational cleavage of Kp-154. All kisspeptins
share an Arg-Phe-NH2 motif at the C-terminus, which is
required for biological activity (Roa et al. 2008). The activity
of KISS1 is regulated via the expression of the KISS1 receptor
(KISS1R), an orphan G-protein-coupled receptor GPR54
(Ohtaki et al. 2001).
The KISS1 gene was originally identified as a human
metastasis suppressor gene; however, additional roles have
now been revealed including a fundamental role in
reproductive function. Kisspeptins are known to be involved
in the onset of puberty due to their role in stimulating
hypothalamic GNRH release, being described as the gate-
keeper of reproductive function (Seminara et al. 2003).
Mutations in the KISS1 gene have been shown to be
associated with the onset of precocious puberty and
hypogonadotropism (Luan et al. 2007), whereas inactivating
mutations in KISS1R result in failure to progress through
puberty (de Roux et al. 2003). In addition to their central
control of the gonadotrophic axis, KISS1 has been found to
be important in placentation, pregnancy and cardiovascular
function (Bilban et al. 2004, Hiden et al. 2007, Mead et al.
2007b). The physiological importance of KISS1 is further
verified by the observations that KISS1R is expressed in a
variety of human tissues including hypothalamus, placenta,
aorta, coronary artery and umbilical vein (Janneau et al. 2002,
Mead et al. 2007a).
Of particular importance to placentation is the involve-
ment of KISS1 in cell migration, a process which is of crucial
importance for trophoblast invasion. KISS1 has been shown
to induce focal adhesion and stress fibre formation and also to
phosphorylate focal adhesion kinase and paxillin, the
intracellular signals needed for cell migration, which may
associate with integrins to inhibit migration (Ohtaki et al.
2001). Furthermore, KISS1 has also been shown to diminish
matrix metalloproteinase 9 (MMP9) expression by reduced
NFkb (NFKB1) binding of the MMP9 promoter,
thereby resulting in a reduction of cell migration (Yan et al.
2001). It is specifically Kp-10, produced by first trimester
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trophoblast cells, that has been shown to inhibit migration
(Bilban et al. 2004).
An important role for KISS1 in pregnancy has also been
suggested due to the dramatic increase in circulating KISS1
levels in pregnancy (Horikoshi et al. 2003). Furthermore,
a placental origin for the peptide has been suggested due
to the observation that circulating KISS1 levels fall 5 days
post-delivery compared with non-pregnant concentrations.
However, the exact function for such an elevation within the
gonadotrophin axis remains to be determined as LH levels
are not elevated in pregnancy as would be predicted by the
observed potent stimulation of LH following exogenous
administration of KISS1 (Dhillo et al. 2006).
KISS1 is present at the feto-maternal interface with
abundant expression in the syncytiotrophoblast cells (Bilban
et al. 2004). KISS1R expression has been localised to both the
villous and invasive extravillous cytotrophoblast cells (EVT;
Bilban et al. 2004). Interestingly mRNA and protein
expressions of both KISS1 and KISS1R have been shown to
be higher in first trimester placental trophoblast cells than in
term gestation, contrasting with the increasing circulating
KISS1 levels during pregnancy (Horikoshi et al. 2003, Bilban
et al. 2004). This finding of the highest levels of expression of
KISS1 and KISS1R in early pregnancy coincides with the
time of maximal extravillous cytotrophoblast invasion and
has therefore been suggested to represent a crucial control
mechanism regulating placental development (Bilban et al.
2004). It is therefore suggested that altered placental
expression of KISS1 and/or KISS1R may be associated
with poor placentation and the associated disorder of pre-
eclampsia (PE). Further support for this comes from the
observation of lower circulating KISS1 concentrations in
early second trimester serum samples from women who
subsequently develop PE and intra-uterine growth restriction
(Armstrong et al. 2009).
The objective of the current study was to investigate the
expression of KISS1 and KISS1R in PE. The hypothesis to be
tested was that the increased expression of KISS1 and/or
KISS1R will be associated with PE.
Materials and Methods
After local ethical committee approval and with appropriate
informed consent, placental tissue was obtained from women
undergoing elective surgical termination of pregnancy (TOP)
during early pregnancy (nZ10; gestational age (obtained
from last menstrual period) 8.8G0.9 weeks (meanGS.D.)) and
at delivery in the third trimester from ten women with
normal term pregnancy (gestational age 39.4G1.1 weeks)
and ten women with PE (gestational age 37.6G2.6 weeks).
Term samples from both with normal pregnancy and PE were
obtained from women undergoing elective Caesarean section
prior to labour. Additional early pregnancy placental samples
were collected at St George’s University of London
(London, UK) with ethical approval from Wandsworth
Local Ethics Committee. Doppler ultrasound screening can
characterise pregnancies into distinct groups, reflecting a
proxy measure of the extent to which remodelling of the
spiral arteries has occurred (Prefumo et al. 2004, Whitley et al.
2007). Maternal uterine artery Doppler velocimetry scans
were taken in the Fetal Medicine Unit, St George’s Hospital
from women attending the clinic for elective TOP as
previously described (Prefumo et al. 2004). High-resistance
cases were defined as those with bilateral uterine diastolic
notches and a mean resistance index (RI) O95th percentile.
Normal resistance cases had no diastolic notches and a mean
RI!95th percentile. These resistance groups represent cases
most (high RI; nZ6; gestational age 11.2G0.4 weeks) and
least (normal RI; nZ6; gestational age 11.1G0.3 weeks)
likely to have developed PE had the pregnancy progressed
(Melchiorre et al. 2008, Poon et al. 2009).
All women with PE met the International Society for the
Study of Hypertension in Pregnancy definition (Brown et al.
2001). Clinical data for normal term pregnancy and PE
subjects are shown in Table 1. Biopsies for immunohisto-
chemistry were fixed in formalin, embedded in wax, and
5 mM serial sections were prepared. Biopsies of placental
tissue, collected for RNA extraction, were snap frozen and
stored at K80 8C.
Immunohistochemistry
Single immunohistochemical labelling was carried out using
the Dako REAL EnVision detection system (Dako UK Ltd,
Cambridgeshire, UK). The sections were first deparaffinised
by immersion in xylene followed by rehydration by passing
through descending concentrations of alcohol (100–70%) and
finally immersion in running tap water. Antigen retrieval was
performed by microwave heating these sections for 10 min in
trisodium citrate buffer (10 mM sodium citrate, pH 6.0).
Peroxidase block solution (Dako) was applied to sections
for 5 min to block endogenous peroxidase activity. To
reduce non-specific background staining, Ultra V Block
Table 1 Clinical details of term pregnancy subject groups. Data are
expressed as mean (S.D.)
Normal term
pregnancy Pre-eclampsia P value
Number of subjects 10 10 NA
Maternal age (years) 28 (7.6) 32 (9.6) NS
Maternal BMI (kg/m2) 23.2 (3.3) 24.3 (4.4) NS
Gestational age
(weeks)
38.3 (1.8) 36.2 (2.1) !0.05
Baby weight (kg) 3.6 (0.9) 3.5 (1.08) NS
Systolic blood
pressure (mmHg)
111 (18.6) 152 (10.5) !0.000
Diastolic blood
pressure (mmHg)
81 (15.7) 110 (15.5) !0.000
Proteinuria (g/l) NA 1.9 (1.9) NA
Platelets (!109/l) NA 185 (35.9) NA
Creatinine (mmol/l) NA 66 (7.0) NA
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(Thermo Scientific, Cheshire, UK) was applied to the
sections for 5 min. Slides were then incubated for 1 h with
appropriate mouse monoclonal antibody for either KISS1
(AbD Serotec, Oxford, UK; MCA3219Z; 1:50) or KISS1R
(Novus Biologicals, Cambridge, UK; NLS1926; mouse
monoclonal; 1:100). Specificity of staining was confirmed
using positive control tissue. Negative controls were also
performed in each staining run using no primary antibody.
Analysis of immunohistochemical labelling
All slides were analysed by the same observer (P J W)
who was blinded to pregnancy stage or outcome. For analysis
of placental sections, digital images of five randomly
selected medium-power (!200) fields were captured on
NIS-Elements F2.20 (Nikon UK Ltd, Surrey, UK). As
described previously, the total percentage of positive labelled
cells per !200 magnification field was determined using
the ‘positive pixel count’ function with ImageScope software
(Aperio Technologies Ltd, Bristol, UK; Williams et al. 2010).
Results are expressed as ‘positivity’ that takes into account
both the number of positive pixels and the intensity of
staining. A visual check was performed to ensure accurate
discrimination of immunolabelled regions.
RNA extraction
Total RNA from placental biopsies (50–100 mg) was obtained
using 1 ml of Tri-reagent (Sigma) according to the
manufacturer’s instructions. RNA integrity was determined
using an Agilent Bioanalyzer (Santa Clara, CA, USA) and all
samples had an RNA integrity number O8.0. RNA purity
and concentration were verified using a Nanodrop spectro-
photomer (Thermo Scientific); all RNA samples had an
A260/A280 ratio of 1.85 or greater.
Following RNA extraction, 1 mg of each sample was
reverse transcribed to cDNA in a 20 ml reaction using
QuantiTect Reverse transcription kit (Qiagen). This kit
contains a mix of random and oligo-dT primers thereby
ensuring that cDNA is generated from all regions of
RNA transcripts. The protocol also includes a genomic
DNA elimination step prior to reverse transcription. Reverse
transcription was performed using a Veriti 96-well thermal
cycler (Applied Biosystems, Warrington, UK). The con-
ditions used to generate first strand cDNA were 42 8C
(15 min) and 95 8C (3 min). cDNA was diluted with
nuclease-free water (Applied Biosystems) to a standard
concentration of 1 mg/ml and stored at K80 8C until use.
Preparation of standards for quantitative real-time PCR
Standards for KISS1, KISS1R and for the reference genes
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta (YWHAZ), hypoxanthine phosphor-
ibosyltransferase 1 (HPRT) and succinate dehydrogenase
subunit A (SDHA) were made from cDNA obtained from a
randomly selected control placenta using semi-quantitative
PCR. QuantiTect Primer assays (Qiagen) were used to detect
KISS1 (Hs_KISS1_1_SG; QT00016044; melting tempera-
ture 60 8C) and KISS1R (Hs_KISS1R_1_SG; QT00043134;
melting temperature 60 8C); sequence information for the
primers in these kits is not available. The reference
genes YWHAZ, HPRT and SDHA were assessed using
oligonucleotide primers generating specific intron-spanning
products (Table 2).
The PCR programme comprised an initial denaturation
stage (95 8C, 15 min), amplification (stage I, 94 8C (30 s);
stage II, melting temperature (30 s); stage III, 72 8C (1 min))
and final extension (72 8C, 7 min; 8 8C ‘hold’). Each PCR
(final volume 50 ml) contained 23.5 ml nuclease-free water
(Ambion, Grand Island, NY, USA); 25 ml 2! ReddyMix
PCR master mix containing 2.0 mM MgCl2 and 0.2 mM
of each dATP, dCTP, dGTP and dTTP (ThermoScientific,
Abgene, Surrey, UK); 0.5 mM forward and reverse primers;
and 1 ml cDNA. The annealing temperature and cycle
number of both primers were optimised and used in their
linear range. Agarose gel electrophoresis (2.0–2.5%) and
ethidium bromide staining confirmed the presence of
products at the expected sizes. The resulting PCR product
was extracted (QIAquick gel extraction kit, Qiagen),
sequenced, and results were cross-referenced with NCBI
Nucleotide Blast to determine specificity of the target gene.
After confirmation that the product was specific to the target
gene, extracted PCR products were resuspended in nuclease-
free water to allow preparation of a standard curve ranging
from 107 to 101 copies/ml. Standards were stored at K80 8C
until its use in quantitative real-time PCR (qRT-PCR).
qRT-PCR
qRT-PCR was used to quantify the expressions of KISS1
and KISS1R relative to the reference genes YWHAZ, HPRT
and SDHA. PCRs, set up in duplicate, were carried out in
Table 2 Primer sequences for reference genes used in quantitative RT-PCR
Gene name Forward sequence 5 0–3 0 Reverse sequence 5 0–3 0
Melting
temperature (8C)
Accession
number
YWHAZ CCTGCATGAAGTCTGTAACTGAG TTGAGACGACCCTCCAAGATG 60 NM_003406
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 55 NM_000194.2
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 55 NM_004168.2
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25 ml volumes consisting of 1 ml of template cDNA, 12.5 ml
of 2! QuantiFast SYBR Green PCR (Qiagen), 0.5 mM
forward primer, 0.5 mM reverse primer and 9 ml nuclease-free
water. Real-time PCR was performed on all samples using a
Stratagene Mx3000P using a fast cycling programme
consisting of an initial PCR activation step of 5 min at
95 8C followed by 40 cycles of denaturation at 95 8C for 10 s
and combined annealing and extension step of 60 8C for
30 s. Melt curve analysis was performed at 95–55 8C. A
no-template control and reverse transcription negative
control sample were included in all assays.
PCR efficiencies were determined from the standard
curves and were O97% for all genes. All standard curves
were linear (r2O0.995) from 107 to 101 copies. For each gene,
the sample threshold cycle (Ct) and hence copy number/ml
cDNA was determined from the standard curve using the
MxPro software (Agilent). Normalisation of data was
performed using geNorm software that calculated the
normalisation factor of the reference genes for each
sample (Vandesompele et al. 2002), data are expressed in
arbitrary units.
Western immunoblotting
Normal term pregnancy (nZ10), PE (nZ10) placental tissues
or high-RI (nZ6) and normal-RI (nZ6) early placental
samples were homogenised in lysis buffer (CelLytic MT,
Sigma–Aldrich) containing a protease inhibitor cocktail as per
manufacturer instructions (Sigma–Aldrich). The protein
concentration of the protein-containing supernatant was
determined using a bicinchoninic acid protein assay (Pierce
Biotechnology, Rockford, IL, USA). Each protein sample
(30 mg) was used for western immunoblotting. Proteins were
first separated by SDS–PAGE and then transferred to
polyvinylidene fluoride membranes (Immobilon P, Millipore,
Watford, UK). Membranes were blocked overnight in
10% Marvel in 0.2% Tween Tris-buffered saline at 4 8C.
The following morning, membranes were washed and then
incubated for 1 h in rabbit polycloncal anti-kisspeptin
(Abcam, Cambridge, UK; ab80994; 10 mg/ml), anti-
KISS1R (Abcam; ab100896; 1 mg/ml) or anti-b actin
antibody (Abcam; ab8227; 1/2000), which was used as a
loading control. Membranes were washed before 30 min
incubation in HRP conjugated goat anti-rabbit IgG
secondary antibody (Abcam; ab97080; 1:5000). Immuno-
reactivity was detected using AceGlow Ultra sensitive
chemiluminescence substrate (PeqLab, Sarisbury Green,
UK) according to the manufacturer’s instructions. Mem-
branes were visualised using Quantity One 4.2.1 image
analysis software (Bio-Rad). Data were corrected for
background and then normalised to b-actin expression.
Statistical analysis
All analyses were performed using SPSS for Windows version
17.0 (Chicago, IL, USA). The Kolmogorov–Smirnov test was
used to assess the distribution of data. All data had a normal
distribution and therefore between-group comparisons were
made using a Student’s t-test. The standard value of P%0.05
was considered significant. Unless otherwise stated all data
are expressed as meanGS.E.M.
Results
Immunohistochemistry
KISS1- and KISS1R-positive immunolabellings were present
in all samples examined. KISS1 protein expression was
significantly reduced in PE placental samples (1.21G0.20)
compared with normal term pregnancy (3.72G0.276;
P!0.001). There was also a significant reduction in KISS1
expression between early pregnancy (6.18G0.384) and
term normal pregnancy placenta (P!0.001; Fig. 1). Placental
KISS1R expression was found to be higher in PE
(3.01G0.138) than in normal term pregnancy (1.73G0.125;
P!0.001). Protein expression of KISS1R was also found to
be lower in term pregnancy placental samples than in early
pregnancy samples (4.04G0.199; P!0.001; Fig. 1).
Figure 1 (a) Photomicrographs to show placental expression of
KISS1 and KISS1R in early pregnancy, normal term pregnancy
and PE. Staining was predominantly localised to syncytiotro-
phoblast cells (indicated with open headed arrow) with a small
amount of staining present in villous cytotrophoblast cells
(indicated with diamond headed arrow). Positive labelled cells
appear brown; magnification !200. (b) Graph of immuno-
histochemical labelling for KISS1 and KISS1R. Data are
expressed as meanGS.E.M. positivity.
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Western immunoblotting
Protein expression as determined by western immunoblotting
also identified an increased expression of KISS1 in term normal
pregnancy placenta (20.3G3.31) compared with PE placental
samples (4.9G0.94; P!0.001, Fig. 2). Placental KISS1R
expression was increased in PE (114G3.7) and term normal
pregnancy (24.3G2.81; P!0.001; Fig. 2). Additionally, early
pregnancy samples identified that women with high uterine
artery RI (less spiral artery remodelling and a higher risk of
developing PE) expressed lower levels of KISS1 protein
(39G4.4) than did women with a normal uterine artery RI
and a lower risk of developing PE (177.7G6.8; P!0.001;
Fig. 3). KISS1R expression was also found to be higher in
high-RI placental samples (180.7G6.7) than in normal-RI
placental samples (84G5.1; P!0.001; Fig. 3).
mRNA
mRNA expressions for bothKISS1 andKISS1R as assayed by
qRT-PCR displayed similar expression patterns to that seen
for protein expression (Fig. 4). mRNA expressions of the
three reference genes YWHAZ, HPRT and SDHA did not
vary between groups. The highest levels of expressions for
both KISS1 (2.49G0.144) and KISS1R (2.33G0.064) were
found in early pregnancy placenta compared with normal
term pregnancy (P!0.001; Fig. 4). KISS1 expression was
reduced in PE placental samples (0.286G0.08) compared
with term normal pregnancy (0.95G0.17; PZ0.003; Fig. 3).
However, expression of KISS1R mRNA was significantly
higher in PE (1.57G0.19) than in term normal pregnancy
(0.80G0.13; PZ0.003).
Discussion
This study demonstrates reduced expression of KISS1 and
increased expression of KISS1R in PE compared with control
term pregnancy at both the protein and mRNA levels.
Additionally, this study has confirmed previous observations
of highest levels of expression of both KISS1 and KISS1R in
early pregnancy. The results of this study indicate that reduced
expression of KISS1 and increased expression of KISS1R may
be involved in the pathogenesis of PE due to alterations in
expression at both mRNA and protein levels compared with
normal pregnancy. It is interesting to note that in early
pregnancies screened by uterine artery Doppler ultrasound as
a proxy measure of the extent of uterine vessel remodelling
(which is impaired in PE), there was also reduced KISS1 and
increased KISS1R expressions in those with a high RI
compared with those with normal RI, suggesting that these
differences are apparent early on and at a stage at which the
pathology of PE is becoming established.
The present finding of a reduction in placental KISS1
expression is in agreement with the reports of lower
circulating levels in the first and second trimester of
pregnancy in women who deliver small for gestational age
neonates and who subsequently developed PE and/or intra-
uterine growth restriction and with the suggestion that KISS1
represents a suitable biomarker for PE (Smets et al. 2008,
Armstrong et al. 2009, Logie et al. 2011). KISS1 was originally
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Figure 2 Graph to show protein expression levels determined by
western immunoblotting in term normal pregnancy (NP) and PE.
Photomicrographs show representative samples for each antibody.
Data are shown as meanGS.E.M. relative expression normalised to
b-actin.
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Figure 3 Graph and photomicrographs to show protein expression
levels determined by western immunoblotting in early pregnancy
placental samples from women with high (high-RI) and normal RI
(normal-RI). RI was used as a proxy measure of the extent of uterine
vessel remodelling, which is impaired in PE.
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identified due to its anti-metastatic properties and within full
term placenta and in the trophoblast derived cell line HTR8/
Svneo Kp-10 has been shown to inhibit cell migration (Bilban
et al. 2004, Roseweir et al. 2012). However, this finding has
yet to be reproduced in early pregnancy placental samples.
Furthermore, the current finding is in agreement with the
recent report that has shown decreased expression of KISS1
in women with recurrent early pregnancy loss (Park et al.
2012), again indicating an important role for KISS1 in
establishment of the placenta. The finding of reduced levels of
KISS1 in PE may appear to contradict our understanding
of the pathophysiology of PE, which is accepted to begin
with inadequate trophoblast invasion. However, it has been
suggested that lower levels of KISS1 within the placenta in
pathological pregnancies may signal low invasive capacity,
where reduced invasive capacity would be expected (Smets
et al. 2008). Smets et al. describe how expression of kisspeptin
is highest during the period of maximal trophoblast invasion
and suggest that high invasive capacity is counteracted by the
inhibitory effect of high levels of kisspeptin, and a low
expression of kisspeptin signals low invasive capacity.
Alternatively, smaller less invasive placentae may develop in
PE, which have a reduced capacity to produce KISS1.
A further possible explanation for the decreased expression
of KISS1 in the pathophysiology of PE may relate to the
simultaneous increase in KISS1R, which may serve to
maximise the activity of KISS1 and thereby inhibit
trophoblast migration, which is crucial to the successful
development of the placenta. In this manner the reduced
expressions of both mRNA and protein of KISS1, which in
itself would lead to a reduction in inhibition of cell migration,
are negated via the higher levels of expression of KISS1R,
thereby achieving higher activity levels of KISS1, resulting in
increased inhibition of cell migration. KISS1 has also been
shown to be angiostatic (Ramaesh et al. 2010) and therefore
increased overall KISS1 activity due to increased expression
of KISS1R may result in inhibition of angiogenesis within
human placental vessels leading to the development of PE.
A second explanation for the observed reduction in KISS1
expression in placenta of women with PE may be that KISS1
expression is reduced as a result of the reduced trophoblast
invasion during the early stages of pregnancy that leads to
reduced expression of KISS1 as a mechanism to try to increase
trophoblast invasion and placental development. A further
possible explanation may be because the current study has
examined KISS1, which will identify the smaller peptide
products Kp-54, Kp-14, Kp-13 and Kp-10. To the best of
the authors’ knowledge, with the exception of Kp-10, which
has been studied extensively (Bilban et al. 2004), the function
of the other kisspeptin fragments in human placentation has
not been described. Further functional studies are required
to determine the exact functional effects of each of these
biological active kisspeptins to examine if they all have the
same function within the placenta.
Possible limitations of the present study are that the
reduction in KISS1 and KISS1R expressions in PE may
represent a secondary change rather than being responsible for
the primary pathogenesis of PE; however, the confirmation
of higher levels of KISS1R and lower levels of KISS1 in early
placenta pregnancy samples indicates that these findings are
likely to be important in the early placental changes associated
with PE. Furthermore, the present sample size is relatively
small (nZ10) in each group and these findings need to be
replicated in a much larger cohort to validate the present
findings. Although mRNA and protein expressions mirrored
each other, it is important to consider that altered expression
does not necessarily correlate with altered function and
therefore further functional studies are warranted. A further
possible limitation of the study is the difference in gestational
age at delivery between the term normal pregnancy and PE
sample groups. The obstetric management for women with
PE is delivery, which is frequently preterm, making it difficult
to collect gestational age-matched samples of women who
meet the ISSHP guidelines for diagnosis of PE at full term
(Turner 2010).
This study shows altered expression of KISS1 and its receptor
KISS1R in PE suggesting a role in the pathophysiological
changes that occur in this disorder.
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